Quarterly ResultMay 4, 2026, 07:47 AM
ADC Therapeutics Q1 Net Product Revenue $20.0M; Net Loss $33.0M
AI Summary
ADC Therapeutics reported its first quarter 2026 financial results, with net product revenue increasing to $20.0 million from $17.4 million year-over-year. The company significantly reduced its net loss to $33.0 million, or $0.21 per share, compared to a net loss of $38.6 million, or $0.36 per share, in Q1 2025. Operational updates include anticipated topline data for the LOTIS-5 Phase 3 trial in Q2 2026 and full data for LOTIS-5 and LOTIS-7 by year-end. The company also projects a cash runway extending at least into 2028.
Key Highlights
- Net product revenue increased to $20.0 million in Q1 2026 from $17.4 million in Q1 2025.
- Net loss decreased to $33.0 million ($0.21/share) in Q1 2026 from $38.6 million ($0.36/share) in Q1 2025.
- Research and Development expense decreased to $19.9 million in Q1 2026 from $28.9 million in Q1 2025.
- Cash and cash equivalents were $231.0 million as of March 31, 2026.
- The company expects its cash runway to extend at least into 2028.
- LOTIS-5 Phase 3 topline data is anticipated in Q2 2026, with full data by year-end.
- Full data from the LOTIS-7 Phase 1b trial is also expected by year-end 2026.